These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 22855730)

  • 1. GLP-1 receptor antagonist exendin-(9-39) elevates fasting blood glucose levels in congenital hyperinsulinism owing to inactivating mutations in the ATP-sensitive K+ channel.
    Calabria AC; Li C; Gallagher PR; Stanley CA; De León DD
    Diabetes; 2012 Oct; 61(10):2585-91. PubMed ID: 22855730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exendin-(9-39) corrects fasting hypoglycemia in SUR-1-/- mice by lowering cAMP in pancreatic beta-cells and inhibiting insulin secretion.
    De León DD; Li C; Delson MI; Matschinsky FM; Stanley CA; Stoffers DA
    J Biol Chem; 2008 Sep; 283(38):25786-93. PubMed ID: 18635551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of a Glucagon-Like Peptide 1 Receptor Antagonist Antibody for Treatment of Hyperinsulinism.
    Peterson SM; Juliana CA; Hu CF; Chai J; Holliday C; Chan KY; Lujan Hernandez AG; Challocombe Z; Wang L; Han Z; Haas N; Stafford R; Axelrod F; Yuan TZ; De León DD; Sato AK
    Diabetes; 2023 Sep; 72(9):1320-1329. PubMed ID: 37358194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans.
    Schirra J; Nicolaus M; Roggel R; Katschinski M; Storr M; Woerle HJ; Göke B
    Gut; 2006 Feb; 55(2):243-51. PubMed ID: 15985560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blockade of glucagon-like peptide 1 receptor corrects postprandial hypoglycemia after gastric bypass.
    Salehi M; Gastaldelli A; D'Alessio DA
    Gastroenterology; 2014 Mar; 146(3):669-680.e2. PubMed ID: 24315990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence that glucagon stimulates insulin secretion through its own receptor in rats.
    Kawai K; Yokota C; Ohashi S; Watanabe Y; Yamashita K
    Diabetologia; 1995 Mar; 38(3):274-6. PubMed ID: 7758872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro.
    Parkes DG; Pittner R; Jodka C; Smith P; Young A
    Metabolism; 2001 May; 50(5):583-9. PubMed ID: 11319721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucagon-like peptide-1 is a physiological incretin in rat.
    Wang Z; Wang RM; Owji AA; Smith DM; Ghatei MA; Bloom SR
    J Clin Invest; 1995 Jan; 95(1):417-21. PubMed ID: 7814643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of insulin oversecretion by subcutaneous recombinant human insulin-like growth factor I in children with congenital hyperinsulinism due to defective beta-cell sulfonylurea receptor.
    Katz LE; Ferry RJ; Stanley CA; Collett-Solberg PF; Baker L; Cohen P
    J Clin Endocrinol Metab; 1999 Sep; 84(9):3117-24. PubMed ID: 10487673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of islet hormone release and gastric emptying by endogenous glucagon-like peptide 1 after glucose ingestion.
    Salehi M; Vahl TP; D'Alessio DA
    J Clin Endocrinol Metab; 2008 Dec; 93(12):4909-16. PubMed ID: 18827000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of GLP-1 Signaling in Hypoglycemia due to Hyperinsulinism.
    Danowitz M; De Leon DD
    Front Endocrinol (Lausanne); 2022; 13():863184. PubMed ID: 35399928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exendin-(9-39) is an inverse agonist of the murine glucagon-like peptide-1 receptor: implications for basal intracellular cyclic adenosine 3',5'-monophosphate levels and beta-cell glucose competence.
    Serre V; Dolci W; Schaerer E; Scrocchi L; Drucker D; Efrat S; Thorens B
    Endocrinology; 1998 Nov; 139(11):4448-54. PubMed ID: 9794451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide.
    Kolligs F; Fehmann HC; Göke R; Göke B
    Diabetes; 1995 Jan; 44(1):16-9. PubMed ID: 7813808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A selective nonpeptide somatostatin receptor 5 agonist effectively decreases insulin secretion in hyperinsulinism.
    Juliana CA; Chai J; Arroyo P; Rico-Bautista E; Betz SF; De León DD
    J Biol Chem; 2023 Jun; 299(6):104816. PubMed ID: 37178920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon receptor antagonist-mediated improvements in glycemic control are dependent on functional pancreatic GLP-1 receptor.
    Gu W; Winters KA; Motani AS; Komorowski R; Zhang Y; Liu Q; Wu X; Rulifson IC; Sivits G; Graham M; Yan H; Wang P; Moore S; Meng T; Lindberg RA; Véniant MM
    Am J Physiol Endocrinol Metab; 2010 Oct; 299(4):E624-32. PubMed ID: 20647556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39.
    Edwards CM; Todd JF; Mahmoudi M; Wang Z; Wang RM; Ghatei MA; Bloom SR
    Diabetes; 1999 Jan; 48(1):86-93. PubMed ID: 9892226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defining the role of GLP-1 in the enteroinsulinar axis in type 2 diabetes using DPP-4 inhibition and GLP-1 receptor blockade.
    Aulinger BA; Bedorf A; Kutscherauer G; de Heer J; Holst JJ; Göke B; Schirra J
    Diabetes; 2014 Mar; 63(3):1079-92. PubMed ID: 24296715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exendin-(9-39) Effects on Glucose and Insulin in Children With Congenital Hyperinsulinism During Fasting and During a Meal and a Protein Challenge.
    Stefanovski D; Vajravelu ME; Givler S; De León DD
    Diabetes Care; 2022 Jun; 45(6):1381-1390. PubMed ID: 35416981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.
    Schirra J; Sturm K; Leicht P; Arnold R; Göke B; Katschinski M
    J Clin Invest; 1998 Apr; 101(7):1421-30. PubMed ID: 9525985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons.
    D'Alessio DA; Vogel R; Prigeon R; Laschansky E; Koerker D; Eng J; Ensinck JW
    J Clin Invest; 1996 Jan; 97(1):133-8. PubMed ID: 8550824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.